公开(公告)号：US20050238643A1

公开(公告)日：2005-10-27

申请号：US10495695

申请日：2002-11-12

申请人： Jonathan Arm ,  Nicodemus Tedla ,  Luis Borges

发明人： Jonathan Arm ,  Nicodemus Tedla ,  Luis Borges

IPC分类号： A61K45/00 ,  A61K39/395 ,  A61K45/06 ,  A61P29/00 ,  A61P43/00 ,  C07K16/28

CPC分类号： C07K16/2803 ,  A61K2039/505

摘要： This invention relates to methods for treating rheumatoid arthritis (RA) by administering one or more agents that specifically target LIR-2, LIR-3 and LIR-7. Results disclosed herein indicate that these three LIRs may participate in regulating the activation of leukocytes that infiltrate synovial tissue. Thus, inflammation in the joints of RA patients can be ameliorated by administering agents that modulate expression or function of LIR-2 and/or LIR-3 and/or LIR-7 to reduce or eliminate the activation of monocytes or macrophages present in inflamed joints, or to reduce their recruitment to the site of inflammation. This can be accomplished by modulating LIR-7, which transmits a stimulatory signal, and/or by modulating LIR-2 and/or LIR-3, which when triggered exert an inhibitory effect, or by concurrently modulating two or all three of these LIRs.

摘要翻译： 本发明涉及通过施用一种或多种特异性靶向LIR-2，LIR-3和LIR-7的试剂来治疗类风湿性关节炎（RA）的方法。 本文公开的结果表明，这三种LIR可参与调节渗透滑膜组织的白细胞的活化。 因此，RA患者关节炎症可以通过调节LIR-2和/或LIR-3和/或LIR-7的表达或功能的给药剂来改善，以减少或消除发炎关节中存在的单核细胞或巨噬细胞的活化 ，或减少他们招募到炎症部位。 这可以通过调节传递刺激信号的LIR-7和/或通过调节LIR-2和/或LIR-3来实现，其在触发时发挥抑制作用，或通过同时调节这些LIR中的两个或所有三个 。